Medicare Advantage

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.

General Atlantic affiliate sells 13.2M Alignment Healthcare shares at $19.46 in secondary offering, raising ~$257M with expected close March 4, 2026.

CMS froze $ELV Medicare Advantage enrollment over data compliance issues, triggering 7.23% stock decline as regulatory pressures mount.

CVS and Vertex poised for growth through 2026 via operational improvements and expanded product pipelines. Both companies expected to deliver significant shareholder value.

UnitedHealth faces regulatory challenges and flat Medicare rates in 2027. Diversified business model provides buffer, but cost management and operational efficiency crucial for profitability.